Replies to post #269042 on The Golden Lounge

[BottomBounce]

$FDBL http://friendable.com/

[BottomBounce]

$DNRG Dominovas Energy Corporation, an early stage company, designs, manufactures, markets, and deploys multi-megawatt power plants. The company deploys NextGen clean energy, solid oxide fuel cell and intelligent communications operating system. It offers RUBICON fuel cell system, a modular SOFC system that operates at high temperatures. The company offers its products to fuel cell and sustainable/alternative energy industry in Guinea West Africa and Angola West Africa, as well as private and governmental sectors of other African countries. Dominovas Energy Corporation is headquartered in Atlanta, Georgia.

[ottoman]

PTIE down 62% 07:36 AM EDT, 09/26/2016 (MT Newswires) -- Pain Therapeutics (PTIE) shares fell to their lowest level ever in pre-market trade after the company said the U.S. Food and Drug Administration denied approval for the company's Remoxy capsules in their present form.
PTIE was down 72% at $0.78 recently, a record low if it holds into regular trading. The current 52-week range is between $0.99 and $2.70.
In the complete response letter issued to the company, the FDA said additional actions and data are needed for the approval. However, the letter didn't mention clinical safety, drug efficacy, manufacturing, stability, bioequivalence or any other issues.
The company is planning further discussions with the FDA.
Durect Corporation (DRRX) was also halted in recent pre-market trade. The company licensed the exclusive right to develop and commercialize on a worldwide basis Remoxy ER and other specified opioid analgesics utilizing Durect's Oradur extended-release, abuse-deterrent technology to Pain Therapeutics in December 2002.
DRRX trades in a 52-week range between $0.99 and $2.70.
Under the terms of that license, Pain Therapeutics funds the development program including reimbursing Durect for formulation and other work performed for Pain Therapeutics. Durect may also receive additional payments if certain development and regulatory milestones are achieved. Durect is eligible to also receive royalties of between 6.0% to 11.5% of net sales if Remoxy ER is commercialized, and may receive additional income from the sale of key excipients supplied by Durect for use in the manufacture of Remoxy ER.
Price: 0.78, Change: -1.96, Percent Change: -71.53
http://www.mtnewswires.com Copyright © 2016 MTNewswires. All rights reserved. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.